Overview of lymphoma diagnosis and management.
暂无分享,去创建一个
[1] M. Rosenblum,et al. Paraneoplastic cerebellar degeneration , 1992, Neurology.
[2] H. Rappaport,et al. Morphological criteria in the classification of the malignant lymphomas. , 1970, Proceedings. National Cancer Conference.
[3] J. Piette,et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. , 2006, Archives of internal medicine.
[4] G. Klein,et al. Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: Antibodies to EBV associated Membrane and Viral Capsid Antigens in Burkitt Lymphoma Patients , 1970, Nature.
[5] A. Zelenetz,et al. NCCN: Non-Hodgkin's lymphoma. , 2001, Cancer control : journal of the Moffitt Cancer Center.
[6] A. Bezjak,et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[7] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[8] C. Mayr,et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. , 2003, Haematologica.
[9] N. Ueno,et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen , 2005, Bone Marrow Transplantation.
[10] A. Zelenetz,et al. Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma , 2006, British journal of haematology.
[11] C. Paolo,et al. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas , 2007, Leukemia & lymphoma.
[12] V. Diehl,et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Zelenetz,et al. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell , 1991, The Journal of experimental medicine.
[14] W. Blattner,et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. , 1983, The New England journal of medicine.
[15] A. Zelenetz,et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease , 2004, British journal of haematology.
[16] M. Paulli,et al. Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. , 1997, Leukemia & lymphoma.
[17] M. Weinstock,et al. The changing survival of patients with mycosis fungoides , 1999, Cancer.
[18] G. Salles,et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. , 2000, Blood.
[19] V. Ambrosini,et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma , 2006, Leukemia & lymphoma.
[20] T. Lister,et al. Management of localized non‐Hodgkin's lymphoma: The experience at St. Bartholomew's hospital 1972–1985 , 1989, Hematological oncology.
[21] C. Meijer,et al. Primary and secondary cutaneous CD 30 1 lymphoproliferative disorders : a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment , 2022 .
[22] K. Beal,et al. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] J. Goedert,et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. , 2006, Blood.
[24] L. Caplan,et al. Risk factors for non-Hodgkin's lymphoma according to family history of haematolymphoproliferative malignancies. , 2001, International journal of epidemiology.
[25] S. Pileri,et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. , 2007, Blood.
[26] Dirk Hasenclever,et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.
[27] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[28] Y. Shugart,et al. A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden , 2000, Human Genetics.
[29] E. Campo,et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] N. Harris,et al. Mediastinal large cell lymphoma: An uncommon subset of adult lymphoma curable with combined modality therapy , 1988, Cancer.
[31] C. Meijer,et al. Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment , 2000 .
[32] T L Chorba,et al. Trends in non‐hodgkin lymphoma (NHL) and HIV‐associated NHL deaths in the United States , 2001, American journal of hematology.
[33] S. Pittaluga,et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features , 1996 .
[34] A. Rademaker,et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long‐term follow‐up in newly diagnosed mantle cell lymphoma , 2008, British journal of haematology.
[35] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Fisher,et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] C. Klemke,et al. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome , 2005, The British journal of dermatology.
[39] M. Stolte,et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Tsimberidou,et al. Richter syndrome , 2005, Cancer.
[41] Ruta Bajorunaite,et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.
[42] W. Chan,et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. , 1997, The New England journal of medicine.
[43] M. Calaminici,et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] M. Piris,et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. , 2002, Blood.
[45] S. Horning,et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] K. Franssila,et al. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. , 2003, European journal of cancer.
[47] E. Jaffe,et al. The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma. , 1983, Blood.
[48] Edward J. Lee,et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma , 2004, Cancer.
[49] J. Spivak,et al. Commentary on and reprint of Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG, Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma, in Lancet (1991) 338:1175–1176 , 2000 .
[50] R. Siebert,et al. Familial Hodgkin's and non-Hodgkin's lymphoma: different patterns in first-degree relatives. , 1997, Leukemia & lymphoma.
[51] S. Pittaluga,et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. , 1996, Blood.
[52] T. Starzl,et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. , 1992, The New England journal of medicine.
[53] P. Bastrup-Madsen,et al. Alcohol pain in Hodgkin's disease. , 1953, Lancet.
[54] C. Pascutto,et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles , 2004, Cancer.
[55] M. Djokic. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5 , 2008 .
[56] A. Levis,et al. Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian- , 2007 .
[57] J. Seymour,et al. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. , 2006, Clinical lymphoma & myeloma.
[58] L. Staudt,et al. Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. , 2007 .
[59] V. Diehl,et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). , 2008, Blood.
[60] H. Tilly,et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .
[61] J. Jais,et al. Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. , 1996, Leukemia & lymphoma.
[62] H. Kantarjian,et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] R. Gascoyne,et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. , 2006, Blood.
[64] ONSTANZE,et al. GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .
[65] J. Rodríguez,et al. Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from The Gel‐Tamo Study Group , 2007, European journal of haematology.
[66] A. López-Guillermo,et al. The clinical significance of molecular response in indolent follicular lymphomas. , 1998, Blood.
[67] P. Cohen,et al. Bone marrow and peripheral blood involvement in mantle cell lymphoma , 1998, British journal of haematology.
[68] B. Glimelius,et al. Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience , 1997, European journal of haematology.
[69] D. Weisenburger,et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). , 2006, Blood.
[70] G. Palestro,et al. Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study , 2006, European journal of haematology.
[71] A. Pileri,et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.
[72] M. S. Lewis,et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[73] B. Nathwani,et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] X. Mariette,et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.
[75] D. Weisenburger,et al. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] S. Hamilton-Dutoit,et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. , 2003, The New England journal of medicine.
[77] W. Wilson,et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. , 2002, Seminars in oncology.
[78] A. Varghese,et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. , 1996, Archives of dermatology.
[79] Elaine S. Jaffe,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[80] D. Weisenburger,et al. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. , 1992, American journal of public health.
[81] G. Klein,et al. DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[82] L. Wilson,et al. The changing survival of patients with mycosis fungoides , 1999, Cancer.
[83] L. Kalish,et al. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis , 1993, Cancer.
[84] H. Greenberg. Paraneoplastic cerebellar degeneration , 2004, Journal of Neuro-Oncology.
[85] A. Zelenetz,et al. Primary mediastinal large B‐cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999 , 2005, British journal of haematology.
[86] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[87] V. Beral,et al. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. , 2000 .
[88] P. Brousset,et al. Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease. , 1993, Blood.
[89] X. Mariette,et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? , 2005, Blood.
[90] Carl Blomqvist,et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. , 2007, Blood.
[91] L. Specht,et al. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake , 2006, Hematological oncology.
[92] R. Gascoyne,et al. Long‐term disease‐free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation , 2004, British journal of haematology.
[93] R. Willemze,et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. , 2000, Archives of dermatology.
[94] S. Horning,et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[96] M. Shoukri,et al. Primary diagnosis and REAL/WHO classification of non‐Hodgkin's lymphoma by fine‐needle aspiration: Cytomorphologic and immunophenotypic approach , 2003, Diagnostic cytopathology.
[97] R. Fisher,et al. Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014). , 2004 .
[98] C. Craddock,et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation , 2005, The Lancet.
[99] N. Konstantinou,et al. Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. , 2006, Haematologica.
[100] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[101] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[102] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[103] K. van Besien,et al. Primary mediastinal B-cell lymphoma: a review of pathology and management. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] C. Gisselbrecht,et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] R. Advani,et al. Non‐Hodgkin lymphoma of the breast , 2007, Cancer.
[106] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[107] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] A. Zelenetz,et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.
[109] P. Isaacson,et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma , 1991, The Lancet.
[110] S. Tucker,et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. , 2001, International journal of radiation oncology, biology, physics.
[111] J. Raemaekers,et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] A. Varghese,et al. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. , 1999, Archives of dermatology.
[113] S. Pileri,et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. , 1997, The New England journal of medicine.
[114] G. Salles,et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] L. Staudt,et al. The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.
[116] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[117] J. Bosq,et al. Primary Breast Lymphoma , 2003, Leukemia & lymphoma.
[118] H. Tsukuma,et al. Risk of non‐Hodgkin's lymphoma in patients with hepatitis C virus infection , 1999, International journal of cancer.
[119] D. Reece,et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1994, Blood.
[120] N. Harris,et al. Mucosa‐associated lymphoid tissue lymphoma of the stomach , 1999, Cancer.
[121] J. Srigley,et al. Mediastinal large-cell lymphoma. , 1992, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.
[122] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[123] S. Horning,et al. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.
[124] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[125] D. Winfield,et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.
[126] Ash A. Alizadeh,et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.
[127] M. Carrington,et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. , 2002, Blood.
[128] S. Kvaløy,et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[129] A. Varghese,et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.
[130] B. Christensen,et al. Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases , 2004, British journal of haematology.
[131] T. Molina,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.
[132] M. Pfreundschuh,et al. Four versus six courses of a dose‐escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation , 2006, Cancer.
[133] F. Collin,et al. Modification of Kiel and working formulation classifications for improved survival prediction in non-Hodgkin's lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] Y. Natkunam,et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. , 2003, Blood.
[135] J. Itami,et al. Extranodal natural killer/T‐cell lymphoma, nasal type , 2006, Cancer.
[136] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[137] A. Staines,et al. The increasing incidence of non-Hodgkin's lymphoma (NHL): the possible role of sunlight. , 1994, Leukemia & lymphoma.
[138] S. de Vos,et al. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. , 1996, Blood.
[139] R. Hoppe,et al. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. , 1988, The New England journal of medicine.
[140] A. Zelenetz,et al. Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL. , 2006 .
[141] M. Paulli,et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B , 2004, British Journal of Cancer.
[142] D. Weisenburger,et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.
[143] S. Pileri,et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[144] D. Oscier,et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.
[145] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[146] S. Franceschi,et al. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. , 2000, AIDS.
[147] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[148] E. Giné,et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[149] R. Coutinho,et al. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults , 2000 .
[150] M. Tiemann,et al. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease , 2005, European journal of haematology.
[151] K. Hemminki,et al. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. , 2005, Blood.
[152] M. M. Mac Manus,et al. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[153] Konrad Donhuijsen. Patterns of presentation of Hodgkin disease , 1993, Cancer.
[154] J. Armitage,et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] S. Horning,et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. , 1997, Blood.
[156] D. Weisenburger,et al. Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[157] A. Neugut,et al. Incidence rates of the major leukemia subtypes among U.S. Hispanics, Blacks, and non-Hispanic Whites , 2006, Leukemia & lymphoma.
[158] V. Diehl,et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.
[159] J. Askling,et al. Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics , 2006, Cancer Epidemiology Biomarkers & Prevention.